We are live on ! Find out more
ENVB icon

Enveric Biosciences
ENVB

10 hedge funds and large institutions have $283K invested in Enveric Biosciences in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.31% less ownership

Funds ownership: 1.1% → 0.79% (-0.31%)

18% less capital invested

Capital invested by funds: $345K → $283K (-$61.5K)

23% less funds holding

Funds holding: 13 → 10 (-3)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
10
Holders Change
-3
Holders Change %
-23.08%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
3
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$46.7K
2
AI
AdvisorShares Investments
Maryland
+$16.9K
3
Morgan Stanley
Morgan Stanley
New York
+$16.4K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.03K
5
TRCT
Tower Research Capital (TRC)
New York
+$727

Top Sellers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
-$56K
2
Citadel Advisors
Citadel Advisors
Florida
-$27.9K
3
UBS Group
UBS Group
Switzerland
-$19.5K
4
VF
Virtu Financial
New York
-$6.14K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.76K
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
AdvisorShares Investments
Maryland
$125K +$16.9K +1,113 +15%
Renaissance Technologies
2
Renaissance Technologies
New York
$44.8K +$46.7K +3,084 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$34.1K +$2.03K +134 +6%
UBS Group
4
UBS Group
Switzerland
$33.1K -$19.5K -1,285 -36%
VF
5
Virtu Financial
New York
$25K -$6.14K -405 -19%
Morgan Stanley
6
Morgan Stanley
New York
$15.8K +$16.4K +1,085 New
TRCT
7
Tower Research Capital (TRC)
New York
$3.58K +$727 +48 +24%
BlackRock
8
BlackRock
New York
$727 – – –
SS
9
SBI Securities
Japan
$726 -$152 -10 -17%
Bank of America
10
Bank of America
North Carolina
$29 +$30 +2 New
National Bank of Canada
11
National Bank of Canada
Quebec, Canada
$6 – – –
Wells Fargo
12
Wells Fargo
California
$2 – – –
Group One Trading
13
Group One Trading
Illinois
$1 -$30 -2 Closed
Jones Financial Companies
14
Jones Financial Companies
Missouri
$1 – – –
HF
15
HRT Financial
New York
– -$56K -3,385 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$27.9K -1,672 Closed
Fidelity Investments
17
Fidelity Investments
Massachusetts
– -$4.76K -286 Closed
HT
18
Headlands Technologies
Illinois
– -$153 -9 Closed
Barclays
19
Barclays
United Kingdom
– -$42 -3 Closed

ENVB Hedge Fund Activity: Q2 2025 in Review

10 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q2 2025, worth a combined $283K — down 18% from $345K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ENVB and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $46.7K. The largest seller was HRT Financial, exiting entirely with an estimated $56K sold.

  • 10 institutional investors held Enveric Biosciences (ENVB) as of Q2 2025, down from 13 in Q1 2025.
  • Funds reported $283K of Enveric Biosciences stock for Q2 2025, down 18% quarter-over-quarter.
  • 3 funds opened new Enveric Biosciences positions in Q2 2025 and 6 closed out, a net change of -3 holders.
  • The largest Enveric Biosciences buyer in Q2 2025 was Renaissance Technologies, an estimated $46.7K added.
  • The largest Enveric Biosciences seller in Q2 2025 was HRT Financial, an estimated $56K sold.

Based on aggregated 13F filings for Q2 2025.